Bevacizumab vedotin is an antibody-drug conjugate ( ADC ). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis ( Apoptosis ), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer [1].
In Vitro, Bevacizumab vedotin (1 mg; 72-120 h) exhibits high serum stability[1]. Bevacizumab vedotin (30-165 min) rapidly and completely releases its MMAE payload under the mediation of cathepsin B[1]. Bevacizumab vedotin (0-10 μg/mL; 48 h) potently inhibits the proliferation of U87, HepG2 and MCF-7 cells, with IC50 values of 14.1712 μg/mL, 0.6483 μg/mL and 0.1442 μg/mL, respectively[1]. Bevacizumab vedotin (1 μg/mL; 48 h) induces apoptosis in U87, HepG2 and MCF-7 cells after 48 h of treatment[1]. Treatment with Bevacizumab vedotin (0.1-20 μg/mL; 48 h) induces G1-phase cell cycle arrest in U87 and HepG2 cells[1]. Bevacizumab vedotin (0.01-0.1 μg/mL; 12-48 h) inhibits the migration of MCF-7 cells in a concentration- and time-dependent manner, and downregulates the expression of VEGF-A in MCF-7 cells[1]. Bevacizumab vedotin (0.1-1 μg/mL; 4-48 h) exhibits anti-angiogenic activity, reduces tube formation (junctions and branches) in HUVECs, downregulates VEGF-A expression, and upregulates VEGFR-2 expression in HUVECs[1].
References:
[1]. Li Y, et al. Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023;137:106575.
In Vitro, Bevacizumab vedotin (1 mg; 72-120 h) exhibits high serum stability[1]. Bevacizumab vedotin (30-165 min) rapidly and completely releases its MMAE payload under the mediation of cathepsin B[1]. Bevacizumab vedotin (0-10 μg/mL; 48 h) potently inhibits the proliferation of U87, HepG2 and MCF-7 cells, with IC50 values of 14.1712 μg/mL, 0.6483 μg/mL and 0.1442 μg/mL, respectively[1]. Bevacizumab vedotin (1 μg/mL; 48 h) induces apoptosis in U87, HepG2 and MCF-7 cells after 48 h of treatment[1]. Treatment with Bevacizumab vedotin (0.1-20 μg/mL; 48 h) induces G1-phase cell cycle arrest in U87 and HepG2 cells[1]. Bevacizumab vedotin (0.01-0.1 μg/mL; 12-48 h) inhibits the migration of MCF-7 cells in a concentration- and time-dependent manner, and downregulates the expression of VEGF-A in MCF-7 cells[1]. Bevacizumab vedotin (0.1-1 μg/mL; 4-48 h) exhibits anti-angiogenic activity, reduces tube formation (junctions and branches) in HUVECs, downregulates VEGF-A expression, and upregulates VEGFR-2 expression in HUVECs[1].
References:
[1]. Li Y, et al. Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023;137:106575.